Scholarlink

Purpose <p>Patients with liver disease often experience nutritional insufficiency due to an interplay of metabolic disturbances and dietary alterations leading to decreased muscle mass and the development of protein-calorie malnutrition (PCM). This study aimed to evaluate the prevalence of PCM in patients with steatotic liver disease (alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD)) and their impacts on mortality and healthcare utilization.</p> Methods <p>We identified hospitalizations with ALD, MASLD, and PCM using International Classification of Diseases codes in the National Inpatient Sample from 2016 to 2020. Descriptive analyses compared hospitalizations with and without PCM. Multivariable linear models adjusting for confounders evaluated the association between PCM and inpatient mortality, length of stay (LOS), and total charges.</p> Results <p>PCM was found to be significantly more prevalent among hospitalizations with ALD or MASLD than those with neither (ALD 175.5 versus 51.8; MASLD 149.0 vs. 50.7; neither: 49.3 per 1000 hospitalizations; <i>p</i> &lt; 0.001). Among hospitalizations with ALD nor MASLD, PCM was significantly associated with higher mortality (ALD adjusted odds ratio [aOR] 1.61; 95% CI 1.55–1.66; MASLD aOR 1.89; 95% CI 1.84–1.93), LOS (ALD 3.78 more days; 95% CI 3.67–3.88; MASLD 5.65 more days; 95% CI 5.53–5.77), and total charges (ALD $45,013; 95% CI $42,549–$47,477; MASLD $74,502; 95% CI $71,214–$77,789).</p> Conclusion <p>We found a higher prevalence of PCM among individuals with ALD compared to those with MASLD nor neither condition. PCM was associated with increased mortality, LOS, and total charges in those with ALD and MASLD. Our findings underscore the importance of early identification and management of PCM in patients with steatotic liver disease to mitigate adverse outcomes and reduce healthcare utilization.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence and Impact of Protein-Calorie Malnutrition in Hospitalized Patients with Steatotic Liver Disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月5日

查看全文
  • C. Greb Alexandra,
  • Kim Sowon,
  • Roney Andrew,
  • Ting Peng-sheng,
  • N. Limketkai Berkeley,
  • Chen Po-Hung

摘要

Purpose

Patients with liver disease often experience nutritional insufficiency due to an interplay of metabolic disturbances and dietary alterations leading to decreased muscle mass and the development of protein-calorie malnutrition (PCM). This study aimed to evaluate the prevalence of PCM in patients with steatotic liver disease (alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD)) and their impacts on mortality and healthcare utilization.

Methods

We identified hospitalizations with ALD, MASLD, and PCM using International Classification of Diseases codes in the National Inpatient Sample from 2016 to 2020. Descriptive analyses compared hospitalizations with and without PCM. Multivariable linear models adjusting for confounders evaluated the association between PCM and inpatient mortality, length of stay (LOS), and total charges.

Results

PCM was found to be significantly more prevalent among hospitalizations with ALD or MASLD than those with neither (ALD 175.5 versus 51.8; MASLD 149.0 vs. 50.7; neither: 49.3 per 1000 hospitalizations; p < 0.001). Among hospitalizations with ALD nor MASLD, PCM was significantly associated with higher mortality (ALD adjusted odds ratio [aOR] 1.61; 95% CI 1.55–1.66; MASLD aOR 1.89; 95% CI 1.84–1.93), LOS (ALD 3.78 more days; 95% CI 3.67–3.88; MASLD 5.65 more days; 95% CI 5.53–5.77), and total charges (ALD $45,013; 95% CI $42,549–$47,477; MASLD $74,502; 95% CI $71,214–$77,789).

Conclusion

We found a higher prevalence of PCM among individuals with ALD compared to those with MASLD nor neither condition. PCM was associated with increased mortality, LOS, and total charges in those with ALD and MASLD. Our findings underscore the importance of early identification and management of PCM in patients with steatotic liver disease to mitigate adverse outcomes and reduce healthcare utilization.